This HTML5 document contains 103 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n29http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/guide-to-pharmacology/
n26http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/national-drug-code-directory/
n19http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/chebi/
n25http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/wikipedia/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/pharmgkb/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/kegg-compound/
n18http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/bindingdb/
n28http://www.drugs.com/cdi/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/property/
n21http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n31http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/iuphar/
n22http://linked.opendata.cz/ontology/sukl/drug/
n23http://linked.opendata.cz/resource/atc/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00379/identifier/drugbank/

Statements

Subject Item
n2:DB00379
rdf:type
n5:Drug
n5:description
Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. [PubChem]
n5:dosage
n6:271B6474-363D-11E5-9242-09173F13E4C5 n6:271B6475-363D-11E5-9242-09173F13E4C5 n6:271B6476-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
10-12 hours
n5:indication
For the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
n5:manufacturer
n15:271B6467-363D-11E5-9242-09173F13E4C5 n15:271B6468-363D-11E5-9242-09173F13E4C5 n15:271B6466-363D-11E5-9242-09173F13E4C5 n15:271B6469-363D-11E5-9242-09173F13E4C5
owl:sameAs
n25:DB00379 n27:DB00379
dcterms:title
Mexiletine
adms:identifier
n4:DB00379 n7:6916 n8:4034 n10:C07220 n11:0597-0068-01 n12:2629 n13:2629 n17:Mexiletine n30:50117271 n31:46505491 n32:PA450488 n33:4178
n5:mechanismOfAction
Mexiletine, like lidocaine, inhibits the inward sodium current required for the initiation and conduction of impulses, thus reducing the rate of rise of the action potential, Phase 0. It achieves this reduced sodium current by inhibiting sodium channels. Mexiletine decreases the effective refractory period (ERP) in Purkinje fibers in the heart. The decrease in ERP is of lesser magnitude than the decrease in action potential duration (APD), which results in an increase in the ERP/APD ratio. It does not significantly affect resting membrane potential or sinus node automaticity, left ventricular function, systolic arterial blood pressure, atrioventricular (AV) conduction velocity, or QRS or QT intervals
n5:packager
n15:271B6463-363D-11E5-9242-09173F13E4C5 n15:271B6464-363D-11E5-9242-09173F13E4C5 n15:271B6461-363D-11E5-9242-09173F13E4C5 n15:271B6462-363D-11E5-9242-09173F13E4C5 n15:271B645F-363D-11E5-9242-09173F13E4C5 n15:271B6460-363D-11E5-9242-09173F13E4C5 n15:271B645D-363D-11E5-9242-09173F13E4C5 n15:271B645E-363D-11E5-9242-09173F13E4C5 n15:271B6465-363D-11E5-9242-09173F13E4C5 n15:271B645B-363D-11E5-9242-09173F13E4C5 n15:271B645C-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
Approximately 10% is excreted unchanged by the kidney. The urinary excretion of N-methylmexiletine in man is less than 0.5%.
n5:synonym
1-(2',6'-Dimethylphenoxy)-2-aminopropane Mexiletinum 1-(2,6-Dimethylphenoxy)-2-propanamine 1-Methyl-2-(2,6-xylyloxy)ethanamine Mexilétine (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane (+-)-1-(2,6-Dimethylphenoxy)propan-2-amine Mexiletina
n5:toxicity
Symptoms of overdose include nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, AV heart block, asystole, ventricular tachyarrythmia, including ventricular fibrillation, cardiovascular collapse, and coma.
n5:volumeOfDistribution
* 5 to 7 L/lg
n22:hasAHFSCode
n26:24-04-04-08
n5:foodInteraction
Take with food to reduce irritation.
n5:proteinBinding
50-60%
n5:salt
n5:synthesisReference
Margarita Ortiz-Marciales, Kun Huang, Viatcheslav Stepanenko, Melvin De Jesus, Wildeliz Correa, "Method of synthesizing enantiopure mexiletine analogues and novel b-thiophenoxy and pyridyl ethers." U.S. Patent US08012901, issued September 06, 2011.
n18:hasConcept
n19:M0013719
foaf:page
n21:mex1261.shtml n28:mexiletine.html n29:mexiletine.htm
n5:IUPAC-Name
n9:271B647B-363D-11E5-9242-09173F13E4C5
n5:InChI
n9:271B6481-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n9:271B6480-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n9:271B647D-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n9:271B647E-363D-11E5-9242-09173F13E4C5
n5:SMILES
n9:271B647F-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n9:271B6490-363D-11E5-9242-09173F13E4C5 n9:271B6479-363D-11E5-9242-09173F13E4C5
n5:logP
n9:271B6477-363D-11E5-9242-09173F13E4C5 n9:271B6492-363D-11E5-9242-09173F13E4C5 n9:271B647A-363D-11E5-9242-09173F13E4C5
n5:logS
n9:271B6478-363D-11E5-9242-09173F13E4C5
n5:pKa
n9:271B6493-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:C01BB02
n5:H-Bond-Acceptor-Count
n9:271B6487-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n9:271B6488-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n9:271B6482-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n9:271B6483-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n9:271B6485-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n9:271B6484-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n9:271B6486-363D-11E5-9242-09173F13E4C5
n5:absorption
Well absorbed (bioavailability 90%) from the gastrointenstinal tract.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
31828-71-4
n5:category
n5:containedIn
n14:271B646B-363D-11E5-9242-09173F13E4C5 n14:271B646C-363D-11E5-9242-09173F13E4C5 n14:271B646A-363D-11E5-9242-09173F13E4C5 n14:271B6473-363D-11E5-9242-09173F13E4C5 n14:271B6471-363D-11E5-9242-09173F13E4C5 n14:271B6472-363D-11E5-9242-09173F13E4C5 n14:271B646F-363D-11E5-9242-09173F13E4C5 n14:271B6470-363D-11E5-9242-09173F13E4C5 n14:271B646D-363D-11E5-9242-09173F13E4C5 n14:271B646E-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n9:271B648C-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n9:271B648E-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n9:271B648F-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n9:271B6491-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n9:271B648B-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n9:271B648A-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n9:271B648D-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n9:271B647C-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n9:271B6489-363D-11E5-9242-09173F13E4C5